Rubicon Research Q1FY27 Net Profit Jumps to ₹824.49 Cr Standalone, ₹847.81 Cr Consolidated
Rubicon Research reported standalone Q1FY27 net profit of ₹824.49 Cr and consolidated net profit of ₹847.81 Cr. The company acquired an 85% stake in Arinna Lifesciences for ₹1,759.17 million. The timeline for utilizing IPO proceeds was extended to March 31, 2027. A scheme of amalgamation for Kia Health Tech was approved.
The announcement includes substantial financial performance figures, a significant acquisition, and a corporate restructuring (amalgamation), all of which are material to investors.
The company reported strong financial results with significant year-on-year growth in revenue and profit. The acquisition of Arinna Lifesciences and the ongoing amalgamation process indicate strategic growth initiatives.
Rubicon Research Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on August 14, 2026. The Board of Directors approved these results in a meeting that commenced at 3:00 PM IST and concluded at 4:15 PM IST.
On a standalone basis, the company reported a total income of ₹4,301.41 crore (43014.1 million), with revenue from operations at ₹4,277.30 crore (42773.0 million). Profit before tax stood at ₹1,106.57 crore (11065.7 million), and net profit after tax was ₹824.49 crore (8244.9 million). Basic earnings per share were ₹4.99.
Consolidated figures showed a total income of ₹5,400.21 crore (54002.1 million), including revenue from operations of ₹5,343.38 crore (53433.8 million). Profit before tax was ₹1,103.72 crore (11037.2 million), and the net profit after tax was ₹847.81 crore (8478.1 million). Basic earnings per share were ₹5.13.
The company also provided updates on significant corporate actions. The Board had previously approved a Scheme of Amalgamation of Kia Health Tech Private Limited with Rubicon Research Limited, which was filed with the Registrar of Companies on August 3, 2026. Additionally, during the quarter, Rubicon Research acquired an 85% stake in Arinna Lifesciences Limited for a total consideration of ₹1,759.17 million (175.917 crore), completed on April 30, 2026. Subsequent to the quarter, a subsidiary, AdvaGen Holdings’ Inc., acquired a manufacturing facility in New Jersey, USA, for USD 2.9 million (₹24.13 crore). The timeline for utilizing unutilized IPO proceeds has been extended to March 31, 2027.
What to do with a filing like this
Rubicon Research Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rubicon Research Limited. Read the original for the full detail.